Cytokines as therapeutic agents and targets in heart disease

Dubņika, Arita; Manoukian, Martin A.C.; Mohammadi, M. Rezaa; Parekh, Mansi; Gurjarpadhye, Abhijit Achyut; Inayathullah, Mohammed; Dubniks, Viktors; Lakey, Jonathan R. T.; Jayakumar, R.

doi:10.1016/j.cytogfr.2018.08.003

Cited by 12 publications

(9 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytokines are a specific class of molecules secreted by immune cells that act by binding with high affinity to target cell surface receptors, thereby regulating cellular functions [ 34 , 35 , 36 ]. Cytokines include lymphokines produced by lymphocytes and mononuclear factors produced by mononuclear macrophages.…”

Section: The Emerging Of Cancer Immunotherapymentioning

confidence: 99%

Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy

Wang

Liu

2022

Molecules

View full text Add to dashboard Cite

Messenger RNA (mRNA) is being developed by researchers as a novel drug for the treatment or prevention of many diseases. However, to enable mRNA to fully exploit its effects in vivo, researchers need to develop safer and more effective mRNA delivery systems that improve mRNA stability and enhance the ability of cells to take up and release mRNA. To date, lipid nanoparticles are promising nanodrug carriers for tumor therapy, which can significantly improve the immunotherapeutic effects of conventional drugs by modulating mRNA delivery, and have attracted widespread interest in the biomedical field. This review focuses on the delivery of mRNA by lipid nanoparticles for cancer treatment. We summarize some common tumor immunotherapy and mRNA delivery strategies, describe the clinical advantages of lipid nanoparticles for mRNA delivery, and provide an outlook on the current challenges and future developments of this technology.

show abstract

Section: The Emerging Of Cancer Immunotherapymentioning

confidence: 99%

Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy

Wang

Liu

2022

Molecules

View full text Add to dashboard Cite

show abstract

“…The identification of signals responsible for myocardial dysfunction is highly relevant for early diagnosis of heart failure in cancer patients and for designing effective therapeutic interventions. Despite most of the studies pointing to a negative impact of the tumour on cardiac function, it is to be considered that cancer cells may also release molecules with potential cardioprotective properties, such as granulocyte colony stimulating factor (G-CSF) and granulocyte/macrophage colony stimulating factor (GM-CSF) (Dubnika et al 2018). Therefore, the effect that any specific cancer may have on the myocardium likely depends on the balance between the 'negative' and 'positive' factors that it produces.…”

Section: From Cancer To Heartmentioning

confidence: 99%

Mechanisms underlying the cross‐talk between heart and cancer

Brancaccio

Pirozzi

Hirsch

et al. 2019

The Journal of Physiology

View full text Add to dashboard Cite

Cardiovascular diseases and cancer remain the leading cause of death worldwide. Despite the fact that these two conditions have long been considered as distinct clinical entities, recent epidemiological and experimental studies suggest that they should be contemplated and treated as co-morbidities. Heart failure represents nowadays a well-established complication of cancer, primarily as a consequence of the aggressive use of cardiotoxic anti-cancer treatments. On the other hand, the provocative idea that heart failure can prime carcinogenesis has started to emerge, though the molecular basis is still to be fully elucidated. This review summarizes the current knowledge on the mechanisms underlying the bidirectional communication between the failing heart and the cancer. We will discuss and/or speculate on the role of molecular mediators released by either the tumour or the heart that can potentially link heart failure and cancer.

show abstract

“…Indeed, the immune system plays a crucial role in initiating and progressing inflammatory signals following cardiac stress or injury 10 . The contribution of immune response in normal and stressed cardiac composition, development, function, and repair introduces an exciting paradigm to the primary prevention of cardiac fibrosis 11–13 . However, insufficient healing response to adverse left ventricular (LV) remodeling may develop heart failure (HF) over time, associated with chronic inflammation 14 .…”

Section: Introductionmentioning

confidence: 99%

“…10 The contribution of immune response in normal and stressed cardiac composition, development, function, and repair introduces an exciting paradigm to the primary prevention of cardiac fibrosis. [11][12][13] However, insufficient healing response to adverse left ventricular (LV) remodeling may develop heart failure (HF) over time, associated with chronic inflammation. 14 Hence, ischemic HF can be considered a state of chronic expansion of the immune system and loss of normal immunosuppressive systems.…”

mentioning

confidence: 99%

CAR‐T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectives

Abdalla,

Miao,

Ahmed

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Heart diseases remain the primary cause of human mortality in the world. Although conventional therapeutic opportunities fail to halt or recover cardiac fibrosis, the promising clinical results and therapeutic efficacy of engineered chimeric antigen receptor (CAR) T cell therapy show several advancements. However, the current models of CAR‐T cells need further improvement since the T cells are associated with the triggering of excessive inflammatory cytokines that directly affect cardiac functions. Thus, the current study highlights the critical function of heart immune cells in tissue fibrosis and repair. The study also confirms CAR‐T cell as an emerging therapeutic for treating cardiac fibrosis, explores the current roadblocks to CAR‐T cell therapy, and considers future outlooks for research development.

show abstract

Cytokines as therapeutic agents and targets in heart disease

Cited by 12 publications

References 127 publications

Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy

Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy

Mechanisms underlying the cross‐talk between heart and cancer

CAR‐T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectives

Contact Info

Product

Resources

About